Pear Therapeutics Public Company (Nasdaq:PEAR)

Primary contact

πŸš€ Merged with Thimble Point Acquisition Corp. on June 22, 2021. in a SPAC deal worth $1.6B, raising $450M in the process.
Pear Therapeutic is a pioneer in Prescription Digital Therapeutics, or PDTs, operating at the intersection of biotechnology and software technology. The company discovers, develops, and delivers clinically-validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has a pipeline of products and product candidates across therapeutic areas, including mental health disorders, severe insomnia and multiple sclerosis. Its lead product, reSET, treats Substance Use Disorder and was the first PDT to receive marketing authorization from the FDA to treat disease. Pear's second product, reSET-O, was meant for the treatment of Opioid Use Disorder.
Primary contact

Funding πŸ’°

Total $284M
Select investors Temasek Holdings, Novartis, EDBI, SoftBank Vision Fund, Arboretum Ventures, JAZZ Venture Partners, 5AM Ventures, Bridge Builders Collaborative, Trustbridge Partners

Key people πŸ§‘β€πŸ€β€πŸ§‘

Last update: September 4, 2021